Rebif (interferon beta-1a subcutaneous injection) — Medica

relapsing forms of multiple sclerosis (clinically isolated syndrome, relapsing remitting disease, or active secondary progressive disease)

Initial criteria

Patient has a relapsing form of multiple sclerosis (clinically isolated syndrome, relapsing remitting disease, or active secondary progressive disease)
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

Patient has a relapsing form of multiple sclerosis (clinically isolated syndrome, relapsing remitting disease, or active secondary progressive disease)
Patient experienced a beneficial clinical response when assessed by at least one objective measure OR experienced stabilization, slowed progression, or improvement in at least one symptom (motor function, fatigue, vision, bowel/bladder function, spasticity, walking/gait, or pain/numbness/tingling sensation)
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

1 year